Literature DB >> 33151095

Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management.

Nikita Consul1, Behrang Amini2, Juan Jose Ibarra-Rovira2, Katherine J Blair2, Tanya W Moseley2, Ahmed Taher2, Komal B Shah2, Khaled M Elsayes2.   

Abstract

OBJECTIVE: Li-Fraumeni syndrome (LFS) is a rare autosomal-dominant inherited syndrome containing a germline mutation in the TP53 gene, which predisposes to oncogenesis. Leukemia and tumors of the brain, soft tissues, breasts, adrenal glands, and bone are the most common cancers associated with this syndrome. Patients with LFS are very susceptible to radiation, therefore the use of whole-body MRI is recommended for regular cancer screening. It is important to recognize the common tumors associated with LFS on MRI, and it is also important to be aware of the high rate of false-positive lesions.
CONCLUSION: Whole-body MRI is useful for the detection of cancer in patients who come for regular screening; however, it is associated with pitfalls about which the radiologist must remain aware.

Entities:  

Keywords:  Li-Fraumeni syndrome; cancer; genetic; screening; whole-body MRI

Mesh:

Year:  2020        PMID: 33151095     DOI: 10.2214/AJR.20.23008

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

Review 1.  Melanoma in patients with Li-Fraumeni syndrome (Review).

Authors:  Florica Sandru; Mihai Cristian Dumitrascu; Aida Petca; Mara Carsote; Razvan-Cosmin Petca; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

2.  Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings.

Authors:  Zishi Fang; Yan Su; Hailang Sun; Ming Ge; Zhan Qi; Chanjuan Hao; Suyun Qian; Xiaoli Ma
Journal:  BMC Pediatr       Date:  2021-12-27       Impact factor: 2.125

3.  Case Report: Triple Primary Malignant Tumors of the Esophagus, Stomach, and Colon in a Patient With Genetic Analysis.

Authors:  Xiaoli Zhan; Lingzhe He; Kai Song; Shuliang Cao; Erhong Meng; Yuedong Wang
Journal:  Front Genet       Date:  2021-07-09       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.